A 10-Year, Post-marketing, Observational, Registry to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Acronyms ESPRIT
- Sponsors Abbott Laboratories; AbbVie
- 26 Sep 2016 Interim results will be presented at the 25th European Academy of Dermatology and Venereology Congress (EADV), as per AbbVie media release.
- 08 Mar 2016 Six year interim results presented at the 74th Annual Meeting of the American Academy of Dermatology
- 02 Mar 2016 Six year interim results will be presented at the upcoming 74th Annual Meeting of the American Academy of Dermatology (AAD), as per AbbVie media release.